Stryker Co. (NYSE:SYK) Given Average Rating of “Moderate Buy” by Analysts

Stryker Co. (NYSE:SYKGet Free Report) has been given a consensus recommendation of “Moderate Buy” by the fifteen ratings firms that are presently covering the company, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold rating and twelve have issued a buy rating on the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $331.52.

Several analysts have recently issued reports on SYK shares. Truist Financial lifted their target price on shares of Stryker from $330.00 to $345.00 and gave the company a “hold” rating in a research report on Wednesday, January 31st. UBS Group lifted their price target on shares of Stryker from $289.00 to $297.00 and gave the company a “neutral” rating in a research report on Thursday, November 9th. Morgan Stanley lifted their price objective on shares of Stryker from $300.00 to $320.00 and gave the company an “equal weight” rating in a report on Monday, December 4th. Royal Bank of Canada lifted their price objective on shares of Stryker from $345.00 to $360.00 and gave the company an “outperform” rating in a report on Wednesday, January 31st. Finally, Wells Fargo & Company boosted their price target on shares of Stryker from $336.00 to $364.00 and gave the stock an “overweight” rating in a report on Wednesday, January 31st.

Check Out Our Latest Report on SYK

Insider Activity at Stryker

In other Stryker news, Director Srikant M. Datar sold 500 shares of the company’s stock in a transaction dated Thursday, November 16th. The shares were sold at an average price of $291.92, for a total value of $145,960.00. Following the transaction, the director now directly owns 4,316 shares in the company, valued at approximately $1,259,926.72. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other Stryker news, Director Ronda E. Stryker sold 201,146 shares of the stock in a transaction that occurred on Monday, February 5th. The shares were sold at an average price of $342.90, for a total value of $68,972,963.40. Following the completion of the sale, the director now owns 3,755,128 shares of the company’s stock, valued at $1,287,633,391.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Srikant M. Datar sold 500 shares of the stock in a transaction that occurred on Thursday, November 16th. The shares were sold at an average price of $291.92, for a total transaction of $145,960.00. Following the completion of the sale, the director now directly owns 4,316 shares of the company’s stock, valued at approximately $1,259,926.72. The disclosure for this sale can be found here. In the last three months, insiders have sold 262,725 shares of company stock valued at $86,880,191. Insiders own 5.90% of the company’s stock.

Hedge Funds Weigh In On Stryker

Several large investors have recently added to or reduced their stakes in the company. Avantax Advisory Services Inc. lifted its stake in Stryker by 9.3% in the fourth quarter. Avantax Advisory Services Inc. now owns 9,884 shares of the medical technology company’s stock valued at $2,960,000 after buying an additional 844 shares during the last quarter. Checchi Capital Advisers LLC lifted its stake in Stryker by 1.3% in the fourth quarter. Checchi Capital Advisers LLC now owns 3,738 shares of the medical technology company’s stock valued at $1,119,000 after buying an additional 49 shares during the last quarter. Ieq Capital LLC lifted its stake in Stryker by 1.8% in the fourth quarter. Ieq Capital LLC now owns 31,276 shares of the medical technology company’s stock valued at $9,366,000 after buying an additional 544 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in Stryker by 3.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 681,784 shares of the medical technology company’s stock valued at $204,166,000 after buying an additional 19,996 shares during the last quarter. Finally, QRG Capital Management Inc. lifted its stake in Stryker by 389.5% in the fourth quarter. QRG Capital Management Inc. now owns 52,489 shares of the medical technology company’s stock valued at $15,718,000 after buying an additional 41,766 shares during the last quarter. 76.24% of the stock is currently owned by institutional investors.

Stryker Trading Up 0.9 %

NYSE SYK opened at $342.72 on Thursday. The company has a quick ratio of 0.97, a current ratio of 1.58 and a debt-to-equity ratio of 0.59. The firm has a market cap of $130.20 billion, a PE ratio of 41.54, a price-to-earnings-growth ratio of 2.79 and a beta of 0.90. The company has a 50 day moving average price of $305.85 and a 200 day moving average price of $288.70. Stryker has a 52 week low of $249.98 and a 52 week high of $346.59.

Stryker (NYSE:SYKGet Free Report) last posted its quarterly earnings results on Tuesday, January 30th. The medical technology company reported $3.46 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.27 by $0.19. The business had revenue of $5.82 billion during the quarter, compared to analysts’ expectations of $5.60 billion. Stryker had a net margin of 15.44% and a return on equity of 22.99%. The business’s quarterly revenue was up 11.8% on a year-over-year basis. During the same quarter last year, the company posted $3.00 earnings per share. As a group, sell-side analysts forecast that Stryker will post 11.87 EPS for the current fiscal year.

Stryker Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, January 31st. Investors of record on Friday, December 29th were paid a $0.80 dividend. This represents a $3.20 dividend on an annualized basis and a yield of 0.93%. This is a boost from Stryker’s previous quarterly dividend of $0.75. The ex-dividend date of this dividend was Thursday, December 28th. Stryker’s dividend payout ratio is presently 38.79%.

Stryker Company Profile

(Get Free Report

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies.

Further Reading

Analyst Recommendations for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.